FDA & CDC Clarify VAERS Reporting Duties Under NCVIA

Vaccine manufacturers and post-market surveillance teams operating under 21 CFR Part 600 should note that FDA and CDC have reissued detailed guidance on VAERS reporting obligations, reinforcing the statutory requirements embedded in the National Childhood Vaccine Injury Act of 1986 (NCVIA). The clarification arrives as VAERS has surpassed two million cumulative reports since 1990, a volume that underscores the system's central role in post-licensure safety monitoring.

Under NCVIA, healthcare providers carry two non-discretionary reporting obligations: any adverse event listed by the vaccine manufacturer as a contraindication to subsequent doses, and any event appearing in the Reportable Events Table within the specified post-vaccination timeframe. Manufacturers should confirm that their pharmacovigilance SOPs map directly to the Reportable Events Table and that lot-level trending data is structured to support FDA's parallel monitoring of individual vaccine lots.

Both FDA and CDC conduct independent review of submitted reports. FDA's analysis focuses on whether a reported event is adequately reflected in current labeling or Emergency Use Authorization prescribing information; CDC's review feeds into broader public health signal detection. Regulatory actions that can follow from VAERS data include labeling revisions, Fact Sheet updates, public and HCP communications, or a directive requiring the manufacturer to conduct additional post-market studies, outcomes that carry direct implications for regulatory affairs and medical affairs functions.

The guidance also addresses data integrity. Knowingly submitting a false VAERS report with intent to mislead HHS constitutes a federal offense under 18 U.S. Code § 1001, punishable by fine and imprisonment. QA and compliance leads should ensure that internal training programs reflect this statutory language, particularly where third-party vendors or CROs contribute to adverse event data collection.

Reports can be submitted electronically at vaers.hhs.gov, by fax to 1-877-721-0366, or by mail; the VAERS contact line at 1-800-822-7967 remains available for submission assistance. A current copy of the Reportable Events Table is accessible through the same channel.

Regulatory affairs leads should treat the reissued Q&A as a prompt to audit VAERS submission workflows against the Reportable Events Table timeframes before the next scheduled pharmacovigilance review cycle.

Source: FDA Vaccines, Blood & Biologics via What's New RSS Feed, 17 August 2026.